Are Magic Mushrooms the Key to Better Mental Health Medicine?

How One Company is Radically Changing the Way We Approach Depression, Anxiety, Addiction, and Other Mental Health Struggles

Bright Minds Biosciences (CSE: DRUG) is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain. Their portfolio of drugs accentuate the therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects. The recent public offering and listing on the Canadian Stock Exchange brought in $25.9 million for continued growth and research. Bright Minds is shifting the way we approach mental health by offering novel therapies for disorders and addictions that are otherwise underserved. 


Taking Inspiration from Nature to Treat Those in Need


A Different Take on Mental Health Treatment

Unique Approach – Better Health is threading the needle between trendy psychedelics and traditional medication by deriving novel compounds that don’t fall fully into either category. Their innovative approach to treatment operates in a similar way to psilocybin, without the “trip” typically associated with magic mushrooms. Moreover, the drugs aren’t operating the same way an SSRI does, which is good news for people who experience negative side-effects from such treatments. Better Health is developing a patented suite of drugs that deliver the best of both worlds, while radically changing how we view mental health medication. 

Successful Public Offering – Better Health recently raised $25.9 million dollars in their public offering, uplisting on the Canadian Stock Exchange. The millions raised is earmarked for R&D and other growth efforts, while the uplisting gives Better Health increased visibility for the global market. 

An Incredible Team The team at Bright Minds have decades of experience in their respective fields, and are bringing their stellar track record along with them. Notable achievements include; a company sale worth $160 million (done in one year), over 550 publications and 100 patents, faculty status at Stanford and Columbia, and a suite of commercially successful drugs. 

Massive Market Potential The market for mental health drugs is estimated at $48.4 billion in 2020 and is expected to grow at a CAGR of 6.6% from 2020-2027. Meanwhile, the market for addiction treatment is forecast to reach $31.17 billion by 2027. Better Health’s drugs will be at the forefront of both of these markets, as they will be used to treat depression, anxiety, opioid addiction, and more. 


Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

Bright Minds Biosciences Inc. (CSE:DRUG) (“Bright Minds” or the “Company”) is pleased to announce that it has closed its previously announced underwritten public offering (the “Offering”) of units (the “Units”) of the Company. Eight Capital acted as lead underwriter and sole bookrunner in connection with the Offering on behalf of a syndicate of underwriters including Stifel GMP, Beacon Securities Limited and Haywood Securities Inc. (collectively, the “Underwriters”).

 Pursuant to the terms of the Offering, the Company issued 3,419,883 Units, including 116,883 Units issued pursuant to the exercise of the Underwriters’ over-allotment option, at a price per Unit of $7.57 for aggregate gross proceeds of $25,888,514.31. Each Unit consists of one common share (each a “Common Share”) and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $9.46 per Warrant until March 17, 2024, subject to adjustment and acceleration in certain events. If the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange (the “CSE”) is greater than $13.25 per Common Share for any 10 consecutive trading days, the Company shall have the right to accelerate the expiry date of the Warrants to a date that is at least 30 trading days following the date of the Company issuing a press release disclosing such acceleration.

The net proceeds of the Offering will be used by the Company for research and development activities, as well as working capital and general corporate purposes.

In connection with the Offering, the Underwriters were paid fees for their services in the amount of $916,317.13 plus expenses and received compensation warrants entitling them to purchase an aggregate of 132,666 Common Shares at a price of $7.57 per Common Share for a period of thirty-six months following closing. 39,000 of such compensation warrants will be subject to a hold period of four months and one day.

Find out more at Bright Minds


A Shift In Perspective 

In an Observer article, Dr. Alan Kozikowski, Bright Mind’s Chief Scientific Officer and Co-Founder, says simply, “we’re trying to reinvent psilocybin.” It’s hard to argue with that kind of elegance. So why go about reinventing a psychedelic compound in the first place? Because it works. 

In the 1950s, the pharmaceutical company Sandoz artificially synthesized psilocybin, the active compound in magic mushrooms, packaging them in a pill they called Indocybin. This mushroom-derived medicine was used by therapists to effectively, safely treat depression and other disorders, right up until 1970 when psilocybin was classified as a Schedule 1 drug. That put the kibosh on almost all further research for psilocybin based medications for the next 40+ years. 

Recently though, huge strides have been made in the area of clinical research for psychoactive mushrooms. Spurred on by a rise in depression rates, opioid abuse, and the undesired side-effects from SSRIs, the FDA granted Compass Pathways research permission for mushrooms as a treatment for depression in 2018. Not long after, Johns Hopkins University opened its Center for Psychedelic and Consciousness Research, where scientists are evaluating psilocybin for use in various treatments. 

Dr. Kozikowsk thinks that we would be much further along in treating ailments like depression and anxiety by now if it weren’t for the drug war, so Bright Minds is doing their best to catch up. Now that the overall optics on psychedelic treatments for mental health disorders has changed, it seems like maybe the world at large is ready for a new approach to mental health. Based on their $25.9 million public offering, we think Bright Minds is definitely on the list of companies to watch in this space. 

With the market for mental health drugs estimated at $48.4 billion in 2020 and the market for addiction treatment forecast to reach $31.17 billion by 2027, Better Health’s drugs will be well positioned to disrupt the market share of traditional treatments. 


In the News/Recent PR


Do You Even Shroom? 

So how does all this work anyway? If we know that psilocybin can be used to treat mental health issues, but we don’t want people to have to go through an Alice in Wonderland psychedelic journey every time they feel a little blue (as fun as that might be), what do we do? If you’re Bright Minds Biosciences, you use cutting edge science to develop drugs that function the same way psilocybin does, only without the trip… or at least a truncated version. 

The way most mental health drugs work, including Bright Minds’, is by regulating serotonin. Serotonin plays a big role in mood, appetite, sleep, and important brain functions. An imbalance often leads to health complications and mental health instability. Serotonin (5-HT) receptors are scattered across the central nervous system, from the brain to the spinal cord, and these receptors co-localize with cholinergic, GABAergic and glutamatergic neurons. Serotonin receptor agonists can influence these neurotransmitter systems and have a profound effect on mental health issues. 

Which is where the shrooms come into play. Currently available treatments, like selective serotonin reuptake inhibitors (SSRIs), act by preventing reuptake of serotonin or modulating the transport of serotonin in the central nervous system, and are not specific to any of the 14 receptor subtypes. As a result, these drugs have side effects, and patients have a limited response to treatment. Bright Minds research has found that psilocybin and psilocin (the human body converts the former into the latter) activate certain neurotransmitters in the brain, including 5-HT2A, 5-HT2B, and 5-HT2C. Since 5-HT2B can cause an irregular heartbeat, and complications in people with heart valve issues, Bright Minds is focused on deriving 2A and 2C agonists. 

In animal trials, Bright Mind’s patented drugs that work specifically on 5-HT2C have been shown to have an effect on “impulse control” including nicotine uptake. The implications in eating disorders and opioid misuse are huge. “What we’re aiming for is something that’s safe enough that you can take it at night, go to bed, and wake up in the morning with a clarified brain,” Dr. Kozikowski says. “You’ve gotten rid of the pain, you’re no longer depressed.” 

As of now, there is still a small “trip” associated with the drugs that work on the 2A receptors. These drugs would be administered under the care of a physician, and would theoretically only need to be taken a few times for long-lasting effects. People suffering from severe depression, anxiety, and PTSD would have (in conjunction with therapy) lasting relief from their ailments. 

Currently, Bright Minds is undergoing extensive animal trials before beginning their human studies. The results are promising so far, and the money raised in their recent public offering is being put to good use in furthering their goal of treating underserved populations with their novel therapies. 


Stages of Bright Mind’s Pipeline of Drugs


The Future of Mental Health Treatments

Leading the Way Bright Minds is positioning themselves as a leader in the treatment of mental health disorders using psilocybin anologs. They have prestigious partners like the National Institute of Health in Washington, D.C., the University of Texas at Galveston, the Medical College of Wisconsin, and more, helping them further their research into other areas of treatment. 

Public Perceptions – The public perception of psychedelic treatments for mental health is shifting radically. Since the opening of Johns Hopkins University’s Center for Psychedelic and Consciousness Research, there has been more and more news about the use of psychedelics like psilocybin performing as well or better than current therapies, without the negative side-effects. Judging by Bright Mind’s own public offering, everyone is pretty excited by the opportunities these alternate therapies pose. 

Overall Efficiency – Current medications for depression and anxiety can be quite costly long-term, and most people have difficulties getting dosages right or experience undesirable side-effects. With Bright Mind’s treatments, a patient would only need to take the drugs a few times during a therapy session to experience long-term effects. In some cases they might take the drugs at night before bed, in which case they would not be experiencing the negative effects of SSRIs, which can often cause drowsiness or a lack of focus. 

Need Unfortunately the COVID-19 Pandemic has been devastating for the mental health landscape. Lack of social interaction, job loss, and death of family members has skyrocketed rates of depression around the world. The need for effective, safe solutions for mental health issues has never been greater. 



[one_halfs] [one_half]

Ian McDonald

[/one_half] [one_half]

Mr. McDonald is an entrepreneur and former Investment Banker. Prior to BMB, he served on the management team at a TSX-listed gold mining company. In that capacity, McDonald developed and implemented the corporate strategy as it relates to M&A and capital markets resulting in a $160 million sale within one year.

Previously, he worked in a senior role at a Canadian Investment Bank and in private equity in Vancouver, London and Toronto. Under McDonald’s guidance, clients raised hundreds of millions of dollars in capital. Ian has served as a member of the Board of Directors of several TSX Venture Exchange, Canadian Securities Exchange-listed and private companies.

[/one_half][/one_halfs] [one_halfs] [one_half]

Dr. Alan Kozikowski Ph.D

[/one_half] [one_half]

Trained at Michigan, Berkeley, and Harvard, Dr. Kozikowski began his career as an organic chemist at the University of Pittsburgh. Following his interests in the applications of chemistry to biological problems, he moved on to the Mayo Clinic, and then assumed a position at the Georgetown University Medical Center as Director of the Drug Discovery Program. After a decade at Georgetown, he led a research group at the University of Illinois at Chicago in the Department of Medicinal Chemistry.

Specifically, Dr. Kozikowski’s continued efforts to identify possible treatments for Alzheimer’s disease have resulted in the advancement of the natural product huperzine A to the clinic. He has also developed a new PET imaging agent for use in prostate cancer diagnosis, which is in the clinic. Other novel inventions have been created, with a number of these moving into the clinical realm. A new company Apotheca Therapeutics Inc. has been founded to advance small molecule kinase inhibitors for the treatment of brain cancers.

 Dr. Kozikowski has experience running biotechnology companies, including being CEO of Starwise Therapeutics, developing novel HDAC6 inhibitors for use in Fragile X syndrome, Charcot Marie Tooth disease and Rett therapy. Dr. Kozikowski was also president of Vela Therapeutics, focused on rapidly advancing therapies for these orphan indications.

Dr. Kozikowski is world renown for his work on psychoactive substances, including novel analogs of PCP and cocaine which showed potential to decrease harm to users. 

He also has over 550 publications and over 100 patents to his name.

[/one_half][/one_halfs] [one_halfs] [one_half]

Dr. Revati Shreeniwas MD

[/one_half] [one_half]

Prior to entering industry, Dr. Shreeniwas was a practicing physician and served as faculty at Stanford and Columbia University. She has spent the last two decades as a physician researcher in the pharmaceutical industry. She is passionate about bringing novel therapeutics to patients with an unmet clinical need.

 Dr. Shreeniwas has served as an executive level clinical expert with operational knowledge in leading complex programs for a range of therapeutics (Phase I-IV studies). She has worked on several drugs that have gone on to be approved and are commercially successful, including Tracleer Lexiscan, Natrecor, Rytary, Esbriet, Sunosi and Talzenna.

[/one_half][/one_halfs] [one_halfs] [one_half]

Ryan Cheung

[/one_half] [one_half]

Ryan Cheung is the founder and managing partner of MCPA Services Inc., Chartered Professional Accountants, in Vancouver, B.C. Leveraging his experience as a former auditor of junior venture and resource companies, Mr. Cheung serves as a director and officer or consultant for public and private companies, providing financial reporting, taxation and strategic guidance.

He has been an active member of the Chartered Professional Accountants of British Columbia (formerly Institute of Chartered Accountants of British Columbia) since January 2008. Mr. Cheung holds a diploma in accounting from the University of British Columbia and a Bachelor of Commerce in international business from the University of Victoria.




Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase during the Campaign. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - Bright Minds (DRUG)
  • Amount & Form of Compensation - $78,000 in cash
  • Who Paid for the Campaign & Position with Company if any - Bright Minds (DRUG)
  • Period of Campaign - 01/14/2021 - 04/14/2021
What securities of the Profiled Issuers do we hold? The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
  • Name of Issuer & Ticker Symbol - Bright Minds (DRUG)
  • Number of Shares We or our Affiliates Hold - NA
  • Price We Paid Per Share - NA
  • Date Issued - NA

Related Post

Go to top